Ligand Pharmaceuticals Director Unloads: Investor Guide
A director sold a chunk of Ligand Pharmaceuticals stock, prompting questions about intent and impact. This guide brea...
A concise guide on selecting core crypto assets for beginners who plan to buy and hold for the long term.
28,656 articlesA director sold a chunk of Ligand Pharmaceuticals stock, prompting questions about intent and impact. This guide brea...
Analysts stage a fresh look at Tesla’s 2027 price target, signaling a measured path ahead as product rollouts and cas...
Tech stocks wobbled Friday as yields spiked, triggering a risk-off pullback. This piece lays out where to position wh...
PIMCO dismisses Trump’s NATO exit threats as noise, calling them a paper tiger. The note arrives as investors weigh t...
A former SWIFT official punctured rumors that Ripple XRP could be integrated into SWIFT's payments network. At the sa...
Senate Democrats rolled out a sweeping housing plan to curb corporate ownership of single-family homes and redirect t...
Brookfield Corporation just bought back a substantial amount of its own stock. The move raises questions about whethe...
Pharmaceutical tariffs could quietly raise out-of-pocket drug costs and slow medical innovation. This guide explains ...
A recent SEC Form 4 shows a Teladoc executive sold roughly $71,000 worth of stock. This article breaks down what that...
A seemingly casual moment between two public figures sparked a wave of chatter online. In this article, we unpack why...
As SpaceX eyes a potential mega-IPO, a veteran market strategist says the issue could force a broad rotation, unlocki...
When a top executive sells stock, the market takes notice. This deeper look at Bristow Group's just sold helps you se...